How Does Urolithin A Work? Mechanism of Action, Per the Research

Urolithin A is not a peptide but a small polyphenol-derived metabolite, and it appears frequently alongside longevity and mitochondrial-health literature. It is not produced by the plants people eat; it is produced in the gut. A comprehensive review of urolithin metabolism described urolithins as microbial transformation products of ellagitannins and ellagic acid, formed by specific gut bacteria, with substantial between-person variation in which urolithins are produced (PMID 35118817). That conversion step is the starting point of any mechanistic discussion, because the circulating molecule is the metabolite rather than the dietary precursor.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. It summarises published mechanism-of-action research and does not describe protocols, doses or expected outcomes.

The Short Answer: Mitophagy Is the Core Proposed Mechanism

Across the published literature, the mechanism most consistently attributed to urolithin A is induction of mitophagy, the autophagy pathway that selectively tags and degrades damaged or dysfunctional mitochondria. A 2021 study in muscular dystrophy models reported that urolithin A improved muscle function by inducing mitophagy (PMID 33827972), and a 2024 Alzheimer's disease study reported that urolithin A restored mitophagy and lysosomal function in the models studied (PMID 38753870). A 2024 review of natural autophagy activators grouped urolithin A among compounds described as activating autophagy pathways (PMID 38467543).

The logic researchers describe runs roughly as follows: mitochondria accumulate damage; damaged mitochondria leak reactive oxygen species and mitochondrial DNA; mitophagy removes them; removing them restores the quality of the remaining mitochondrial pool. Urolithin A is positioned in this literature as a pharmacological trigger for that recycling step rather than as a direct stimulant of mitochondrial biogenesis.

Established vs. Proposed: A Working Distinction

Step One: Gut Microbial Conversion

Urolithin A does not come pre-formed in pomegranate, walnuts or berries. The 2022 review described ellagitannins being hydrolysed to ellagic acid and then converted by resident gut bacteria into urolithins, with individuals clustering into different "urolithin metabotypes" depending on which bacteria they carry (PMID 35118817). That review also noted that bioactivity work has centred on urolithin A among the family of urolithins (PMID 35118817).

This matters mechanistically because the exposure a given person achieves from food is not a fixed quantity, it depends on the microbiome. Research on direct administration of the metabolite was designed partly to bypass that variability, a rationale the metabolism review discussed (PMID 35118817).

A Microbiota-Liver Signalling Link

Beyond being a product of the microbiome, urolithin A has been described as acting back on it. A 2024 study in chronic alcohol-related liver disease models reported that urolithin A's effect was mediated by MUP1 via a gut-microbiota-liver axis (PMID 38889450). This is animal and mechanistic work, not a human clinical finding.

Signalling: What Pathways Have Researchers Implicated?

ULK1 and the Autophagy Initiation Complex

ULK1 is the kinase that initiates autophagosome formation. A 2024 study in Advanced Science reported that urolithin A engaged an ERK1/2-ULK1 cascade to improve CD8+ T cell fitness in an antitumour immunity context (PMID 38447147). The study's framing, that urolithin A "hijacks" this cascade, describes an upstream kinase route into autophagy induction rather than direct binding to a classical cell-surface receptor (PMID 38447147).

TFEB and Lysosomal Programming

TFEB is a master transcription factor for lysosomal and autophagy gene expression. A study published in 2025 reported that urolithin A inhibited breast cancer progression in the models used by activating TFEB-mediated mitophagy in tumour macrophages (PMID 38615740). The lysosomal arm also appeared in neurodegeneration work: the 2024 Alzheimer's study reported restoration of both mitophagy and lysosomal functions (PMID 38753870). Mitophagy is only completed when the autophagosome fuses with a functional lysosome, so lysosomal capacity is part of the mechanism rather than a side note.

Nrf2 and the Antioxidant Response

A 2022 mouse study reported that urolithin A protected against acetaminophen-induced liver injury via sustained activation of Nrf2 (PMID 35342347). Nrf2 drives transcription of antioxidant and detoxification genes, and this finding describes a second, partly separate branch of activity from mitophagy induction (PMID 35342347). It is animal work in an acute toxicity model.

Mitophagy Receptors: FUNDC1 and the Broader Machinery

Mitophagy itself runs through receptor proteins on the outer mitochondrial membrane. A 2023 study in Redox Biology examined FUNDC1-dependent mitophagy, reporting that neutrophil extracellular traps drove intestinal microvascular endothelial ferroptosis by impairing that pathway (PMID 37812880). That paper is useful background for understanding which molecular machinery mitophagy inducers are proposed to engage, and it links mitophagy failure to ferroptotic cell death (PMID 37812880).

Downstream Physiology Described in the Literature

Inflammation and the cGAS/STING Axis

One of the clearer mechanistic bridges between mitochondrial quality control and inflammation involves cytosolic mitochondrial DNA. A 2024 Nature Communications paper reported that mitophagy curtailed cytosolic mtDNA-dependent activation of cGAS/STING inflammation during ageing (PMID 38280852). In that framework, damaged mitochondria release DNA into the cytosol, which the cGAS sensor reads as a danger signal; clearing those mitochondria removes the trigger (PMID 38280852). This is a proposed route by which a mitophagy inducer could influence inflammatory tone, and the paper is a mechanism study rather than a human trial.

Skeletal Muscle

The 2021 Science Translational Medicine study reported that urolithin A improved muscle function by inducing mitophagy in muscular dystrophy models (PMID 33827972). More recently, a 2026 Nature Reviews Drug Discovery review of treatments for sarcopenia placed mitochondrial and muscle-targeted approaches within the wider landscape of candidate interventions for age-related muscle decline (PMID 42706321). Review articles summarise a field; they do not establish efficacy for any single compound.

Brain and Neurodegeneration Models

A 2019 Nature Neuroscience study reported that mitophagy inhibited amyloid-β and tau pathology and reversed cognitive deficits in models of Alzheimer's disease (PMID 30742114). The 2024 Alzheimer's study specifically reported that urolithin A improved cognition and restored mitophagy and lysosomal functions in its models (PMID 38753870). Both are preclinical; neither establishes a clinical effect in people with diagnosed disease.

Immune Cells

The CD8+ T cell study reported that the ERK1/2-ULK1 route improved T cell fitness for antitumour immunity (PMID 38447147), and the macrophage study reported TFEB-mediated mitophagy within tumour-associated macrophages (PMID 38615740). Together these describe urolithin A acting inside immune cells as a metabolic modulator rather than as a cytotoxic agent.

Is There a Classical Receptor?

Published mechanistic work on urolithin A does not describe a single named high-affinity cell-surface receptor in the way a peptide hormone has one. Instead, the cited studies describe intracellular signalling nodes: ERK1/2 and ULK1 (PMID 38447147), the transcription factor TFEB (PMID 38615740), and Nrf2 (PMID 35342347). Whether urolithin A binds any of these directly, or acts upstream through changes in mitochondrial state, is not resolved by the papers cited here; the 2024 autophagy-activator review discussed such compounds collectively as autophagy inducers without asserting a unified receptor target (PMID 38467543).

Tolerability and Adverse Findings: What Studies Report

The verified papers summarised on this page are mechanism and efficacy studies in cells and animals, plus reviews; they are not designed as safety trials, and none of the findings described above should be read as a tolerability assessment. The metabolism and bioactivity review discussed urolithins in the context of dietary exposure and gut microbial production (PMID 35118817), while the sarcopenia review framed candidate interventions as still being evaluated in drug-development pipelines (PMID 42706321). Readers looking for adverse-event data should consult primary clinical trial reports and a licensed physician rather than extrapolating from preclinical mechanism studies.

Limitations Worth Holding Onto

• Model species. The muscular dystrophy, Alzheimer's, liver-injury and alcohol-liver findings were reported in animal or cell models (PMID 33827972, PMID 38753870, PMID 35342347, PMID 38889450).
• Disease-specific contexts. Several mechanisms were characterised inside a particular pathology, dystrophic muscle, tumour macrophages, drug-induced liver injury, and may not generalise (PMID 38615740).
• Mitophagy as a general principle. Some of the strongest mitophagy-outcome links, such as the cGAS/STING and amyloid findings, were established for mitophagy itself rather than for urolithin A specifically (PMID 38280852, PMID 30742114).
• Microbiome dependence. Natural exposure varies by metabotype, complicating comparisons between dietary and administered forms (PMID 35118817).

Taken together, the research describes a plausible and internally consistent mechanism, microbial metabolite enters circulation, engages autophagy-initiation and lysosomal-transcription machinery, increases clearance of damaged mitochondria, and thereby reduces mitochondrial-damage-associated signals such as cytosolic mtDNA (PMID 38280852, PMID 38447147). What the cited literature does not provide is a settled account of direct molecular binding, nor human outcome data sufficient to claim clinical effect. Again, this page is educational only and is not medical advice; consult a licensed physician for any individual question.

References

• Mitophagy curtails cytosolic mtDNA-dependent activation of cGAS/STING inflammation during aging (Nature Communications, 2024)
• Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions (Alzheimer's & Dementia, 2024)
• Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease (Nature Neuroscience, 2019)
• Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy (Science Translational Medicine, 2021)
• Neutrophil extracellular traps drive intestinal microvascular endothelial ferroptosis by impairing Fundc1-dependent mitophagy (Redox Biology, 2023)
• Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota (Molecular Nutrition & Food Research, 2022)
• Urolithin A Hijacks ERK1/2-ULK1 Cascade to Improve CD8+ T Cell Fitness for Antitumor Immunity (Advanced Science, 2024)
• Urolithin A protects against acetaminophen-induced liver injury in mice via sustained activation of Nrf2 (International Journal of Biological Sciences, 2022)
• Natural Activators of Autophagy (Biochemistry (Moscow), 2024)
• MUP1 mediates urolithin A alleviation of chronic alcohol-related liver disease via gut-microbiota-liver axis (Gut Microbes, 2024)
• Strengthening muscle for healthy ageing: innovative treatments for sarcopenia (Nature Reviews Drug Discovery, 2026)
• Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages (Journal of Advanced Research, 2025)